Methods and compositions for treating hepatitis C virus
AssigneesIdenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari
InventorsJean-Pierre Sommadossi, Paolo La Colla
Life of this patent
Estimating the term…
Abstract
A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
Claims19
A method for the treatment of a hepatitis C virus infection in a host, comprising administering to the host an antivirally effective amount of a compound of Formula I:
- or a pharmaceutically acceptable salt or ester thereof, wherein:
- R1, R2 and R3 are independently hydrogen;
- monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug;
- acyl;
- alkyl;
- sulfonate ester;
- a lipid;
- an amino acid;
- a carbohydrate;
- a peptide;
- a cholesterol;
- or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently hydrogen or phosphate;
- and
- Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
- X1 and X2 are independently hydrogen, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5;
- and
- R4 and R5 are independently hydrogen, acyl, or alkyl.
A method for the treatment of a hepatitis C virus infection in a host, comprising administering to the host an antivirally effective amount of a compound of Formula III:
- or a pharmaceutically acceptable salt or ester thereof, wherein:
- R1, R2 and R3 are independently hydrogen;
- monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug;
- acyl;
- alkyl;
- sulfonate ester, a lipid;
- an amino acid;
- a carbohydrate;
- a peptide;
- a cholesterol;
- or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently hydrogen or phosphate;
- and
- Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
- X1 and X2 are independently hydrogen, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5;
- and
- R4 and R5 are independently hydrogen, acyl, or alkyl.
A method for the treatment of a hepatitis C virus infection in a host, comprising administering to the host an antivirally effective amount of a compound of Formula IV:
- or a pharmaceutically acceptable salt or ester thereof, wherein:
- R1, R2 and R3 are independently hydrogen, monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug;
- acyl;
- alkyl;
- sulfonate ester;
- a lipid;
- an amino acid;
- a carbohydrate;
- a peptide;
- a cholesterol;
- or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently hydrogen or phosphate;
- Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
- X1 is hydrogen, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5;
- and
- R4 and R5 are independently hydrogen, acyl, or alkyl.
Dependencies are inferred from the claim text.